Analysts estimate that by 2025, the “death delaying” market could reach $610 billion. But that doesn’t sit well with Christian Angermayer, who co-founded Cambrian Biopharma and Rejuvenero and has a special interest in his family office Aperon Investment Group. Extending longevity.
“That’s an absurd, fictitious number made up entirely by the cosmetics and supplement industry,” Angermeier said of the $610 billion estimate. In his view, the overall observable markets for longevity plays can be small and then very large.
“Now,” Angermayer told TechCrunch, “the industry b Really It is delaying human death. zeroBecause anti aging products are being sold and are not on the market. We expect them to go from zero to a trillion dollar industry within a decade after the first ones are proven in clinical trials. It will be that much faster.”
He is not alone in believing this. Demand for space seems to be growing rapidly in the VC community, so I spoke with five investors to get a better understanding of where longevity technology is headed and how big the market will be.
According to Samuel Gill of JME Ventures, the possibilities for longevity are “endless.” “The space is just starting and in the next five to 10 years it will infiltrate all aspects of our lives,” he says.
“There are many angles to solving problems for very different groups with different requirements,” he added. Health Age vs. Lifespan, Longevity for Pets vs. Humans, Biotech vs. Health, Seniors vs. Youth, Dependency vs. Autonomy, Prevention vs. Treatment, Analytics, Education, Infrastructure.
That said, some startups in the space still need additional sources of capital. According to LongevityMarketCap newsletter author Nathan Cheng and Sebastian Brunemeier, a partner at HealthSpan Capital, startups at the intersection of biotech and longevity could still use more capital. “The longevity field is relatively low relative to other biotech and private investment sectors,” said the couple. “We expect it will be another five years or more before long-term biotech enters the mainstream investor consciousness.”
There are several reasons why longevity may not attract additional funding. The prospect of longer life can lead to strong opinions about ethics, environmental implications and overpopulation, not to mention the possibility of reversing aging.
But the solutions to the problems of longevity stop solving beyond aging and improving the quality of life.
“The US’s 40 million unpaid family caregivers are not just a small problem,” said Techstars’ Keith Camhi, who leads the Techstars Future of Longevity Accelerator in partnership with Melinda Gates’ Pivotal Ventures.
“Unpaid family care is a key part of our health care system given the size and scope of the economy and what’s happening there, and it shouldn’t be overlooked just because everyone does it voluntarily,” he said.
Startups are betting they can solve this problem, which negatively affects diversity in the workplace. “It completely disrupts careers, and it’s disproportionately for women.
The broad topics covered here may have given you an idea of the breadth of the field of longevity. Read the full survey to learn more about where longevity technology is, where it’s headed, and what these investors are looking for in voice.